Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BDRXBullishIndustry Newsnews

Medium materiality6/10

Biodexa hits 100-patient Serenta milestone in FAP Phase 3; timing update provided

Oct 13, 2026, 8:52 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Enrollment milestones and timing updates in Phase 3 trials commonly reduce execution risk and can spark short-term equity appreciation, especially if investors interpret timing updates as de-risking potential futility outcomes.

AI summary

What happened, with direct paths to the underlying reporting

Biodexa says 100 patients have enrolled in its Serenta Phase 3 trial for Familial Adenomatous Polyposis (FAP) across 29 US sites and five European countries, with two Canadian sites to begin soon. The company also provided an update on the expected timing of a pre-specified futility analysis and database lock. Progress improves timing clarity but data readouts remain uncertain.

BDRX reports 100 patients in Serenta Phase 3 for FAP.
Trial spans 29 US sites, 5 European countries; two Canada sites planned.
Update on futility analysis timing and database lock provided.
Milestone could influence near-term catalysts depending on data readouts.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.